The overexpression of c-Kit in chromophobe renal cell carcinoma (ChRCC) has been
described by comparative gene expression analyses and has been proposed as a possible …

C-kit encodes the membrane-bound tyrosine kinase KIT, whose expression has been
identified in several types of human neoplasms. Recently, KIT has been reported to be a …

KIT is expressed not only in tumors derived from hematopoietic stem cells, melanocytes,
germ cells, mast cells, and interstitial cells of Cajal, but also in other malignancies such as …

KIT expression has not been studied substantially in renal tumors. We analyzed the
immunohistochemical expression for KIT in 256 conventional renal cell carcinomas (RCCs) …

Objective: Overexpression of KIT (CD117), a tyrosine kinase receptor, has been reported in
a variety of tumors, some of which are susceptible to therapy with imatinib mesylate. Our aim …

We analysed gene-expression profiles in 15 surgical specimens of conventional, papillary,
and chromophobe renal cell carcinomas (RCCs) using high-density oligonucleotide arrays …

Background: KIT is a transmembrane tyrosine kinase receptor, expressed in high amounts in
various normal cells. In addition, c-kit mutation or activation is a major pathogenetic event in …

Aims: To investigate the presence and prognostic relevance of KIT expression in paediatric
renal tumours, and to determine whether receptor overexpression is associated with gene …

Purpose: Sarcomatoid (S) renal cell carcinoma (RCC) is an uncommon subtype of RCC with
a poor prognosis because of its local aggressiveness and high metastatic rate. Currently …

Purpose KIT is a target for imatinib mesylate (Gleevec; Novartis Pharma, Basel,
Switzerland). Gastrointestinal stromal tumors (GISTs) express KIT and respond favorably to …